​

Compass Therapeutics (CMPX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CMPX Stock Forecast

Compass Therapeutics (CMPX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $11.00, with a high of $15.00 and a low of $9.00. This represents a 111.95% increase from the last price of $5.19.

- $3 $6 $9 $12 $15 High: $15 Avg: $11 Low: $9 Last Closed Price: $5.19

CMPX Stock Rating

Compass Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 13 Strong Sell Sell Hold Buy Strong Buy

CMPX Price Target Upside V Benchmarks

TypeNameUpside
StockCompass Therapeutics111.95%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts147
Avg Price Target$9.00$11.50$10.29
Last Closing Price$5.19$5.19$5.19
Upside/Downside73.41%121.58%98.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26313---16
Feb, 26312---15
Jan, 26311---14
Dec, 2529---11
Nov, 2538---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2026Maury RaycroftJefferies$9.00$5.5362.75%73.41%
Feb 13, 2026Craig-Hallum$15.00$6.52130.06%189.02%
Feb 04, 2026Canaccord Genuity$13.00$6.42102.49%150.48%
Jan 06, 2026Sean McCutcheonRaymond James$9.00$4.8984.05%73.41%
Dec 03, 2025Reni BenjaminJMP Securities$10.00$5.2291.57%92.68%
Oct 06, 2025Compass Point$10.00$3.70170.27%92.68%
Apr 02, 2025Andrew BerensLeerink Partners$6.00$1.69255.03%15.61%
Sep 16, 2024Aydin HuseynovCompass Point$5.00$1.65203.03%-3.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2026Cantor FitzgeraldOverweightOverweighthold
Mar 05, 2026JefferiesBuyBuyhold
Mar 05, 2026William BlairOutperformOutperformhold
Mar 05, 2026Raymond JamesOutperformOutperformhold
Feb 13, 2026Craig-HallumBuyinitialise
Jan 06, 2026Raymond JamesOutperformOutperformhold
Jan 05, 2026William BlairOutperforminitialise
Dec 03, 2025Cantor FitzgeraldOverweightinitialise
Dec 03, 2025CitigroupOutperforminitialise
May 13, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-6 $3 $12 $21 $30 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.33$-0.36$-0.42---
Avg Forecast$-0.33$-0.35$-0.40$-0.45$-0.03$0.78
High Forecast$-0.31$-0.32$-0.26$0.34$26.30$1.13
Low Forecast$-0.40$-0.40$-0.63$-1.28$-13.50$0.44
Surprise %-2.86%5.00%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$850.00K----
Avg Forecast-$907.14K$6.22M$61.18M$180.20M$364.77M
High Forecast-$927.76K$8.33M$61.18M$184.89M$488.96M
Low Forecast-$876.22K$4.10M$61.18M$175.51M$240.57M
Surprise %--6.30%----

Net Income Forecast

$-2B $-900M $200M $1B $2B $4B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.49M$-49.38M$-66.49M---
Avg Forecast$-42.49M$-47.76M$-61.25M$-65.80M$788.86K$99.59M
High Forecast$-39.72M$-40.65M$-32.88M$42.75M$3.34B$143.67M
Low Forecast$-51.25M$-50.81M$-79.86M$-162.72M$-1.71B$55.51M
Surprise %-3.39%8.56%---

CMPX Forecast FAQ

Is Compass Therapeutics stock a buy?

Compass Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Compass Therapeutics is a favorable investment for most analysts.

What is Compass Therapeutics's price target?

Compass Therapeutics's price target, set by 13 Wall Street analysts, averages $11 over the next 12 months. The price target range spans from $9 at the low end to $15 at the high end, suggesting a potential 111.95% change from the previous closing price of $5.19.

How does Compass Therapeutics stock forecast compare to its benchmarks?

Compass Therapeutics's stock forecast shows a 111.95% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Compass Therapeutics over the past three months?

  • March 2026: 18.75% Strong Buy, 81.25% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 21.43% Strong Buy, 78.57% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Compass Therapeutics’s EPS forecast?

Compass Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.45, marking a 7.14% increase from the reported $-0.42 in 2025. Estimates for the following years are $-0.03 in 2027, and $0.78 in 2028.

What is Compass Therapeutics’s revenue forecast?

Compass Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $61.18M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $180.2M, and $364.77M for 2028.

What is Compass Therapeutics’s net income forecast?

Compass Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-65.804M, representing a -1.03% decrease from the reported $-66.489M in 2025. Projections indicate $788.86K in 2027, and $99.59M in 2028.